WUHN 株価推移チャート
WUHN 財務
Wuhan General Group (China) Inc
$0
0%
$0
本日現在の状況：Apr 29, 16:46:46 GMT-4
戻る
Wuhan General Group (China) Inc (WUHN) 財務
収入
貸借対照表
現金の流れ
年次
四半期
WUHN 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Wuhan General Group (China) Incの主要な財務諸表は何ですか？
WUHNの主要な財務比率は何ですか？
Wuhan General Group (China) Incの収益はセグメントまたは地域別にどのように分けられていますか？
Wuhan General Group (China) Incは収益を上げていますか？
Wuhan General Group (China) Incに負債はありますか？
Wuhan General Group (China) Incの発行済株式数は何株ですか？
主要データ
前終値
$0.0003
始値
$0.0001
当日レンジ
$0.0001 - $0.0003
52週レンジ
$0.0001 - $0.0005
取引高
156.4K
平均取引高
2.1K
配当利回り
--
1株当たり利益(TTM)
-0.34
時価総額
$16.5K
WUHNとは何ですか？
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The company is headquartered in Cape Town, Western Cape and currently employs 700 full-time employees. The firm is focused on alternative plant-based cannabinoids and mental health therapeutic research. Through its subsidiary, Neur.ai, the Company is engaged in developing a portfolio of receptor agonists based on neurotransformational medicine for the treatment of mental illness. The firm develops and commercializes a range of cannabidiol (CBD) and mushrooms-based products under the Dr. AnnaRx, Medspresso, and Liviana brands. The brands span across a range of premium CBD- and mushroom-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. In addition, the Company's research and clinical trials with psilocybin are aimed at new therapies that seek to help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Its Liviana brand offers CBD-infused raw honey and CBD-infused extra virgin olive oils.